Nerandomilast (BI 1015550): PDE4B inhibitor

For more than 100 years, Boehringer Ingelheim has been leading scientific innovation across a range of respiratory conditions. We remain steadfast in our commitment to create ground-breaking solutions for people living with pulmonary fibrosis. By understanding the disease heterogeneity, molecular pathways, biomarkers, and the mechanisms of fibrosis, we are targeting scientific breakthroughs that seek to restore lung health and prevent pulmonary fibrosis.

Nerandomilast (BI 1015550) is an oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Nerandomilast (BI 1015550) represents the first molecule in a new class of PDE4B inhibitors.

On the heels of the FDA’s Breakthrough Therapy and Orphan Drug Designation in IPF, we are committed to better understand the long-term efficacy and safety of this investigational treatment, with the goal of ensuring that it reaches patients as soon as possible. Nerandomilast (BI 1015550) is being further investigated in the global FIBRONEER™ Phase III program in more than 40 countries in people living with IPF and other progressive fibrosing interstitial lung diseases.

While treatments exist to slow disease progression of pulmonary fibrosis (PF), new treatments are needed to help potentially stop, rather than slow, disease progression. Nerandomilast (BI 1015550) is part of Boehringer Ingelheim’s next wave of potential innovative treatments for PF to preserve lung function and help improve the lives of patients.